Milestone Pharmaceuticals Stock Today

MIST Stock  USD 1.85  0.01  0.54%   

Performance

10 of 100

 
Weak
 
Strong
OK

Odds Of Distress

Over 68

 
High
 
Low
Quite High
Milestone Pharmaceuticals is selling for under 1.85 as of the 21st of November 2024; that is 0.54 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 1.8. Milestone Pharmaceuticals has more than 68 % chance of experiencing financial distress in the next few years of operation. However, it had a very ok returns during the last 90 days. Equity ratings for Milestone Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
9th of May 2019
Category
Healthcare
Classification
Health Care
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company was incorporated in 2003 and is headquartered in Montral, Canada. Milestone Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 53.33 M outstanding shares of which 454.79 K shares are now shorted by private and institutional investors with about 2.46 trading days to cover. More on Milestone Pharmaceuticals

Moving against Milestone Stock

  0.74VIRX Viracta TherapeuticsPairCorr
  0.68VRCA Verrica PharmaceuticalsPairCorr
  0.62VALN Valneva SE ADR Downward RallyPairCorr
  0.55DTIL Precision BioSciencesPairCorr
  0.54EQ EquilliumPairCorr
  0.52ME 23Andme HoldingPairCorr

Milestone Stock Highlights

President CEOJoseph MBA
Thematic IdeaPharmaceutical Products (View all Themes)
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.01260.0133
Notably Down
Slightly volatile
Gross Profit Margin0.720.402
Way Up
Slightly volatile
Total Current Liabilities6.4 M7.2 M
Fairly Down
Slightly volatile
Non Current Liabilities Total28.9 M51.2 M
Way Down
Slightly volatile
Total Assets103.5 M75.2 M
Significantly Up
Slightly volatile
Total Current Assets102.2 M73 M
Significantly Up
Slightly volatile
Debt Levels
Milestone Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Milestone Pharmaceuticals' financial leverage. It provides some insight into what part of Milestone Pharmaceuticals' total assets is financed by creditors.
Liquidity
Milestone Pharmaceuticals currently holds 51.77 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Milestone Pharmaceuticals has a current ratio of 20.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Milestone Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Total Cashflows From Investing Activities

(48.84 Million)
Milestone Pharmaceuticals (MIST) is traded on NASDAQ Exchange in USA. It is located in 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6 and employs 47 people. Milestone Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 99.19 M. Milestone Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 53.33 M outstanding shares of which 454.79 K shares are now shorted by private and institutional investors with about 2.46 trading days to cover. Milestone Pharmaceuticals currently holds about 86.24 M in cash with (46.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Milestone Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Milestone Pharmaceuticals maintains a total of 53.33 Million outstanding shares. Over half of Milestone Pharmaceuticals' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Milestone Ownership Details

Milestone Stock Institutional Holders

InstituionRecorded OnShares
Stonepine Capital Management Llc2024-06-30
1.2 M
Bml Capital Management Llc2024-09-30
1.1 M
Altium Capital Management, Lp2024-06-30
M
Ikarian Capital, Llc2024-06-30
466 K
Boxer Capital Llc2024-09-30
309 K
Adar1 Capital Management Llc2024-06-30
202.5 K
Ancora Advisors Llc2024-06-30
60 K
Envestnet Asset Management Inc2024-06-30
59.5 K
Squarepoint Ops Llc2024-06-30
54.7 K
Blackrock Inc2024-06-30
M
Nantahala Capital Management, Llc2024-06-30
3.5 M
View Milestone Pharmaceuticals Diagnostics

Milestone Pharmaceuticals Historical Income Statement

At this time, Milestone Pharmaceuticals' Interest Income is comparatively stable compared to the past year. Depreciation And Amortization is likely to gain to about 153.2 K in 2024, whereas Selling And Marketing Expenses is likely to drop slightly above 8 M in 2024. View More Fundamentals

Milestone Stock Against Markets

Milestone Pharmaceuticals Corporate Management

Additional Tools for Milestone Stock Analysis

When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.